Lundbeck, the Danish pharmaceutical company, has seen a significant boost in sales, reporting a 16 percent increase in revenue for the third quarter of 2024, totaling 5.7 billion kroner. This surge is driven by strong performance across its product range, with Rexulti—used to treat schizophrenia—leading as the company’s top-selling drug.